US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.
about
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachSubcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Fingolimod for relapsing multiple sclerosis: an update.Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections.Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytesEffects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trialLess Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.Current perspectives on FTY720.Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling.FTY720 (fingolimod) for relapsing multiple sclerosis.Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.Emerging oral drugs for relapsing-remitting multiple sclerosis.Multiple sclerosis and pain.Disease-specific therapy of idiopathic inflammatory demyelinating disorders.Catalytic asymmetric reactions and synthesis of quinones.In multiple sclerosis anxiety, not depression, is related to gender.Interferon treatment may trigger primary headaches in multiple sclerosis patients.Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial.Rifampicin attenuates experimental autoimmune encephalomyelitis by inhibiting pathogenic Th17 cells responses.Artemisinin therapeutic efficacy in the experimental model of multiple sclerosis.
P2860
Q22305854-DE8A86DC-F6F7-48D1-A8F9-8829B052E822Q34028864-3DBFF67F-6490-43AA-976D-4EBDB22967C6Q34618474-C20D7EE1-4C50-4EFE-B1AA-01B975DDAF0AQ34763184-7AE29E55-B939-43A9-907E-76ED91A3AF5BQ35026431-17C84533-51AA-453A-8656-7E23CE209541Q35107430-31FA4606-BA8B-4680-8CC4-E9BF604A623CQ35544804-F2A320F9-B07E-4180-B466-E895104ADE09Q35749074-090FE97D-1033-4342-BF2E-FFD584D50B41Q35915016-32EF7729-EFDB-4250-8A08-511CA95C6F69Q36764024-8186C6B3-5DFF-42A3-8C05-09F392EBEA95Q37072894-749C373B-B5E5-4CCB-9E3E-4B0241A0C839Q37154788-709FA406-3506-4213-A7C9-B9A209B65032Q37668556-F6993F4D-DA50-437B-B6D9-CED5FFE41BE8Q37810989-10040F9E-2830-4946-B6C5-EF4B54AE74F6Q37965547-41DE4242-B91D-4797-A4CC-1EB335608EB8Q38036427-F5CC4D5E-18D4-4724-BC0C-2AA22E196289Q38049628-D1E3F915-CE26-4606-88E6-A59DCE419F26Q38874469-4F2D00A7-C0AE-4DCD-9342-40087612F753Q40871052-0783D3A1-9B47-41C1-9B08-2408FBE2AF43Q42594989-850876E2-73D3-49D1-B892-712D41A4ACDDQ43133299-2B95BCD9-FC73-4D6F-8D6F-284B7C04769EQ47970743-E8F8CBFF-B2EE-4E79-B793-DD9D7E0B7ED7Q48007044-6AC89F42-A064-4114-9D7C-C7E7870DD62B
P2860
US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@ast
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@en
type
label
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@ast
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@en
prefLabel
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@ast
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@en
P1433
P1476
US FDA-approved disease-modify ...... ew of adverse effect profiles.
@en
P2093
Clyde Markowitz
P304
P356
10.2165/00023210-200519030-00005
P577
2005-01-01T00:00:00Z
P6179
1049290479